Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Sales: 2023-2025

Historic Return on Sales for ARS Pharmaceuticals (SPRY) over the last 2 years, with Sep 2025 value amounting to -0.64%.

  • ARS Pharmaceuticals' Return on Sales rose 2265.00% to -0.64% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.64%, marking a year-over-year increase of 2265.00%. This contributed to the annual value of 0.09% for FY2024, which is N/A change from last year.
  • Per ARS Pharmaceuticals' latest filing, its Return on Sales stood at -0.64% for Q3 2025, which was down 20.38% from -0.53% recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Return on Sales ranged from a high of -0.03% in Q4 2024 and a low of -89.88% during Q2 2023.
  • In the last 3 years, ARS Pharmaceuticals' Return on Sales had a median value of -11.96% in 2024 and averaged -28.60%.
  • Data for ARS Pharmaceuticals' Return on Sales shows a peak YoY surged of 7,838bps (in 2025) over the last 5 years.
  • Over the past 3 years, ARS Pharmaceuticals' Return on Sales (Quarterly) stood at -89.88% in 2023, then skyrocketed by 1,097bps to -0.03% in 2024, then skyrocketed by 2,265bps to -0.64% in 2025.
  • Its Return on Sales stands at -0.64% for Q3 2025, versus -0.53% for Q2 2025 and -0.28% for Q1 2025.